Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ: ARCT · IEX Real-Time Price · USD
32.86
+0.73 (2.27%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Company Description

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis.

Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial.

Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 180
CEO Joseph E. Payne M.Sc.

Contact Details

Address:
10628 Science Center Drive, Suite 200
San Diego, California 92121
United States
Phone 858-900-2660
Website arcturusrx.com

Stock Details

Ticker Symbol ARCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001566049
CUSIP Number 03969T109
ISIN Number US03969T1097
SIC Code 2834

Key Executives

Name Position
Joseph E. Payne M.Sc. Founder, President, Chief Executive Officer and Director
Dr. Padmanabh Chivukula Ph.D. Founder, Chief Scientific Officer, Chief Operating Officer and Secretary
Andrew H. Sassine MBA Chief Financial Officer and Director
Neda Safarzadeh Vice President and Head of IR/PR and Marketing
Lance Kurata Chief Legal Officer
Natash O. Bowman Chief Human Resources Officer
Kevin T. Skol Chief Business Officer
Dr. Juergen Froehlich FCPh, M.D., MBA Chief Medical Officer
Dr. Igor Smolenov M.D., Ph.D. Chief Development Officer
Joseph Roberts Controller

Latest SEC Filings

Date Type Title
Jan 10, 2024 CT ORDER Filing
Feb 14, 2020 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 1, 2019 8-K Current Report
Jun 21, 2019 S-8 Securities to be offered to employees in employee benefit plans
Jun 20, 2019 8-K Current Report
May 20, 2019 8-K Current Report
May 13, 2019 8-K Current Report
May 13, 2019 10-Q Quarterly Report
Apr 12, 2019 EFFECT Notice of Effectiveness
Apr 12, 2019 424B3 Prospectus